Home > Healthcare > Pharmaceuticals > Finished Drug Form > carglumic acid market
Get a free sample of Carglumic Acid Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Carglumic Acid Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The carglumic acid industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy.
Some of the eminent market participants operating in the carglumic acid industry include:
The hospital pharmacies segment accounted for a revenue of around USD 77 million in 2023, as they handle the distribution of medications for complex conditions such as hyperammonemia, ensuring that patients receive the necessary treatment.
The global carglumic acid industry was valued at around USD 148.6 million in 2023 and is expected to reach around USD 280 million by 2032 at a CAGR of 7.1%, driven by the growing prevalence of metabolic diseases.
Apothecon Pharmaceuticals Pvt. Ltd., Biophore India Pharmaceuticals Pvt Ltd., Dipharma Francis S.r.l., Eton Pharmaceuticals, KAVYA PHARMA, MANUS AKTTEVA BIOPHARMA LLP, Merck KGaA, NOVITIUM PHARMA LLC, NURAY CHEMICALS, Recordati Rare Diseases Inc., and Suven Life Sciences Limited.
North America carglumic acid market accounted for USD 60.4 million in 2023, attributed to the rising healthcare expenditure in the region, associated with a growing emphasis on specialty care and rare diseases treatment.